Back to MPT Database

Cabotegravir/Levonorgestrel Long-Acting MPT Injectable

Silica hydrogel-based long-acting injectable delivering CAB and levonorgestrel for 3-6 months duration. Currently in preclinical development.

*Also referred to as a dual-prevention product by MATRIX

For more information, contact: Gustavo Doncel at doncelgf@evms.edu / conradinnovations@evms.edu

Development Stage:

Preclinical – Advanced (Pre2)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Injectable (Subcutaneous)

Mechanism of Action:

Integrase strand-transfer inhibitor; progestin

Developer:

  • CONRAD

Funding:

  • Eastern Virginia Medical School
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)

Funding Mechanism:

NIH Adolescent Medicine Trials Network for HIV Interventions (ATN)

Past Funding:

National Institutes of Health (NIH R-61)

Active Ingredient(s):

  • Cabotegravir
  • Levonorgestrel

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database